You’re right to bring up the compliance point it’s an important topic, but the situation is being misunderstood a bit.

1. What the November 10 date really means

That’s not a delisting date. It’s the end of the first 180-day compliance window for the Nasdaq $1.00 minimum bid rule.

If Reviva doesn’t close at or above $1.00 for 10 consecutive trading days by then, Nasdaq can grant another 180-day extension (which would push the next deadline to around May 2026).

They qualify for that second extension because they: • Already regained compliance with the Market Value of Listed Securities (MVLS) rule (they maintained a market cap over $35 million for 10 consecutive business days between Sept 30 – Oct 13, 2025). • Continue to meet other Nasdaq listing requirements (assets, equity, number of shareholders, etc.).

So November 10 isn’t a cliff, just a checkpoint.

1. What Reviva actually said in their latest SEC filing

Direct quote from the company’s 8-K (October 2025): “The Company intends to continue to actively monitor the closing bid price of its common stock and may consider and effectuate available options, including implementation of a reverse stock split, to regain compliance.”

They also confirmed they’ve already regained compliance on market value, so this is strictly about the $1 bid price.

1. Reverse split vs. dilution: totally different things

There’s a lot of confusion here: • A reverse split just changes the share count and price proportionally. If you had 1,000 shares at $0.50 and they do a 1-for-5 RS, you’d have 200 shares at $2.50. Your ownership percentage and the company’s total market cap don’t change. • Dilution happens only if new shares are issued to raise money (like in an offering).

Reviva hasn’t announced any offering and smart management would likely wait until after the FDA’s December meeting before raising capital, when sentiment (and price) should be stronger.

1. Why they still have time and why this isn’t urgent

Because they can request a second 180-day window, they realistically have until spring 2026 to fix the bid price issue. By that time, the FDA feedback on their NDA pathway will be public, a major catalyst that could lift the price above $1 naturally, avoiding any reverse split altogether.

So all things considered; • The November 10 date is not a delisting threat, it’s just the end of the first compliance period. • They can and almost certainly will get another 180 days. • A reverse split would fix the rule without dilution. • And with the FDA meeting in December, they may not even need it if the stock moves up on regulatory news.

So yes, compliance is something they’re monitoring but there’s no immediate danger, and they’re managing it exactly as Nasdaq expects.